GTBP Stock Earnings GT Biopharma Beats EPS for Q1 2024

GTBP Stock  USD 2.86  0.19  6.23%   
Slightly above 56% of all GT Biopharma's retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding GT Biopharma suggests that some traders are interested. GT Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in GT Biopharma. Many technical investors use GT Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
GTBP stock results show that GT Biopharma beat analyst estimates for earnings per share the first quarter of 2024.

Read at investorplace.com
sbwire news
  

GT Biopharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards GT Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

GT Biopharma Fundamental Analysis

We analyze GT Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GT Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GT Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

GT Biopharma is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

GT Biopharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GT Biopharma stock to make a market-neutral strategy. Peer analysis of GT Biopharma could also be used in its relative valuation, which is a method of valuing GT Biopharma by comparing valuation metrics with similar companies.

Peers

GT Biopharma Related Equities

PULMPulmatrix   16.69   
0%
100.0%
SRZNSurrozen   8.96   
0%
53.0%
MNPRMonopar Therapeutics   6.43   
0%
38.0%
VCNXVaccinex   3.65   
0%
21.0%
TARAProtara Therapeutics   3.40   
0%
20.0%
CVKDCadrenal Therapeutics,   3.21   
0%
19.0%
BDRXBiodexa Pharmaceticals   2.71   
0%
16.0%
VRAXVirax Biolabs   2.48   
0%
14.0%
ANEBAnebulo Pharmaceuticals   2.14   
0%
12.0%
QNRXQuoin Pharmaceuticals   1.69   
0%
10.0%
REVBRevelation Biosciences   1.33   
0%
7.0%
NRBONeurobo Pharmaceuticals   0.43   
0%
2.0%
PRAXPraxis Precision   0.26   
1.0%
0%
SABSSAB Biotherapeutics   0.67   
4.0%
0%
AKTXAkari Therapeutics   1.75   
10.0%
0%
VRPXVirpax Pharmaceuticals   4.17   
24.0%
0%
SONNSonnet Biotherapeutics   5.05   
30.0%
0%
ALLRAllarity Therapeutics   10.48   
62.0%
0%

Additional Tools for GTBP Stock Analysis

When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.